Why Is ALAMAR BIOSCIENCES I (ALMR) Stock Moving Today?

Alamar Biosciences stock (Nasdaq: ALMR) declined 5.98% to $24.36 on Friday. The primary driver for the move appears to be a lack of immediate catalysts following a period of high volatility, as the company announced it will report third quarter 2026 financial results on November 3, 2026.

What Happened

Alamar Biosciences, a precision proteomics company based in Fremont, California, confirmed its earnings schedule for the upcoming quarter. The announcement, issued on October 8, 2026, set the date for the third quarter 2026 financial results report as November 3, 2026. This update serves as a key milestone for the company, which is focused on enabling the earliest detection of disease. In the broader market context, Stifel recently maintained a Buy rating on the stock and raised its price target to $32. Additionally, a study published in The Lancet Neurology highlighted that Alzheimer's patients exhibit markedly different biological responses during anti-amyloid antibody treatment with lecanemab, a finding enabled by Alamar's precision proteomics platform.

What The Data Shows

The intraday session reflected significant selling pressure. The stock opened at $26.12, representing a 0.8% gap up from the prior close of $25.91. It reached a session high of $26.60 at 9:30 AM ET before sliding to a session low of $24.34 at 1:20 PM ET. The final price settled at $24.39. Volume stood at 0.3 million shares, which is 0.9 times the three-month daily average. Fundamentals indicate a market cap of $1.9 billion. The company remains unprofitable with a trailing twelve-month EPS of -2.10 and a net margin of -49.5%. However, revenue has grown 195.2% over the trailing twelve months. The 52-week range spans from $18.84 to $39.61. On October 9, 2026, the stock printed one fresh 52-week high and 18 fresh 52-week lows, indicating extreme volatility in the recent tape.

What To Watch

Investors will monitor the November 3, 2026 date for the release of third quarter 2026 financial results. This earnings report is the next scheduled event that could provide clarity on the company's recurring consumables-driven model and its expansion into clinical diagnostics.